Published in J Infect Dis on March 01, 2010
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev (2011) 3.63
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One (2013) 1.36
Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. J Infect Dis (2014) 1.05
Timing, rates, and causes of death in a large South African tuberculosis programme. BMC Infect Dis (2014) 0.91
Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. Drug Des Devel Ther (2015) 0.77
Tuberculosis recurrence in a priority city in the state of São Paulo, Brazil. J Bras Pneumol (2017) 0.75
Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection? Tuberculosis (Edinb) (2017) 0.75
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med (1993) 7.85
Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med (2008) 7.47
Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med (2005) 4.94
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet (2001) 4.33
Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med (2007) 3.32
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr (2009) 2.77
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet (2000) 2.77
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet (1999) 2.62
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis (2003) 2.49
The in vitro evolution of BCG vaccines. Vaccine (2003) 1.80
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS (2003) 1.51
Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis (2009) 1.46
Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis (2010) 1.37
Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2008) 1.34
Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis (2008) 1.28
Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol (2009) 1.22
High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis (2010) 1.20
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS (1999) 1.05
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet (2006) 5.98
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS (2010) 2.60
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis (2010) 2.38
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med (2007) 2.08
HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med (2009) 2.07
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ (2010) 2.03
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One (2012) 1.53
Evaluation of a workplace HIV treatment programme in South Africa. AIDS (2007) 1.52
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS (2010) 1.50
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis (2008) 1.41
Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr (2011) 1.41
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr (2012) 1.39
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis (2003) 1.36
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One (2013) 1.29
Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr (2011) 1.22
Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr (2013) 1.18
Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis (2007) 1.18
Does tuberculosis increase HIV load? J Infect Dis (2004) 1.18
Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials (2010) 1.16
Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS (2010) 1.15
Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS (2010) 1.11
Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol (2012) 1.09
Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former Basotho gold miners. Am J Ind Med (2009) 1.09
A novel HIV treatment model using private practitioners in South Africa. Sex Transm Infect (2012) 1.05
The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. Am J Ind Med (2008) 1.05
Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health (2010) 1.04
Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS (2010) 1.03
Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa. AIDS Patient Care STDS (2011) 0.99
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol (2015) 0.98
Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. PLoS One (2011) 0.97
Polymorphisms in the tumor necrosis factor-alpha gene promoter may predispose to severe silicosis in black South African miners. Am J Respir Crit Care Med (2002) 0.88
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther (2013) 0.87
HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. AIDS (2009) 0.87
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. PLoS One (2012) 0.86
"Proof-of-concept" evaluation of an automated sputum smear microscopy system for tuberculosis diagnosis. PLoS One (2012) 0.85
Opportunities afforded by new drugs for tuberculosis. Lancet Infect Dis (2010) 0.83
HIV infection and chronic chest disease as risk factors for bacterial pneumonia: a case-control study. AIDS (2003) 0.81
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 0.80
The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. Int J STD AIDS (2013) 0.79
Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners. Ann Am Thorac Soc (2015) 0.78
Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health (2014) 0.78
Eligibility for isoniazid preventive therapy in South African gold mines. PLoS One (2013) 0.77
Attitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa. Sex Transm Infect (2007) 0.75
Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa. AIDS (2016) 0.75
Business and AIDS: sectoral challenges and opportunities. AIDS (2007) 0.75
Brief Report: The Effect of Antiretroviral Therapy and CD4 Count on Markers of Infectiousness in HIV-Associated Tuberculosis. J Acquir Immune Defic Syndr (2015) 0.75
Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation Following HIV Diagnosis: a Randomized Trial. J Acquir Immune Defic Syndr (2017) 0.75